-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: keymaster@town.hall.org Originator-Key-Asymmetric: MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ== MIC-Info: RSA-MD5,RSA, X6NFyENfxJjE3ELWt2EfP8CeP7YAImZ3Ze1DNEW614FZ2Xc6WWh/CwjJ/PkgZIse kx+PSqMXPKq4PhHU5r8WhA== 0000789538-95-000002.txt : 199507120000789538-95-000002.hdr.sgml : 19950711 ACCESSION NUMBER: 0000789538-95-000002 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 19941231 FILED AS OF DATE: 19950328 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: ML VENTURE PARTNERS II LP CENTRAL INDEX KEY: 0000789538 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 133324232 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 814-00043 FILM NUMBER: 95523884 BUSINESS ADDRESS: STREET 1: WORLD FINANCIAL CTR N TOWER STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10281-1330 BUSINESS PHONE: 2124491000 10-K 1 FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 1994 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14217 ML VENTURE PARTNERS II, L.P. (Exact name of registrant as specified in its charter) Delaware 13-3324232 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) World Financial Center, North Tower New York, New York 10281-1327 (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 449-1000 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered None None
Securities registered pursuant to Section 12(g) of the Act: Units of Limited Partnership Interest (Title of class) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X] At March 15, 1995, 119,866 units of limited partnership interest ("Units") were held by non-affiliates of the registrant. There is no established public trading market for such Units. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Prospectus of the Registrant dated February 10, 1987, as supplemented by a supplement thereto dated April 21, 1987, are incorporated by reference in Part I and Part II hereof. Portions of the definitive proxy statement relating to the 1995 Annual Meeting of Limited Partners of the Registrant are incorporated by reference in Part III hereof. Portions of the Registrant's Form 10-Q for the quarter ended March 31, 1994 filed with the Securities and Exchange Commission on May 13, 1994 are incorporated by reference in Part I hereof. Portions of the Registrant's Form 10-Q for the quarter ended June 30, 1994 filed with the Securities and Exchange Commission on August 12, 1994 are incorporated by reference in Part I hereof. Portions of the Registrant's Form 10-Q for the quarter ended September 30, 1994 filed with the Securities and Exchange Commission on November 11, 1994 are incorporated by reference in Part I hereof. PART I Item 1. Business. Formation ML Venture Partners II, L.P. (the "Partnership" or the "Registrant") is a Delaware limited partnership organized on February 4, 1986. The General Partners of the Partnership consist of four individuals (the "Individual General Partners") and MLVPII Co., L.P. (the "Managing General Partner"), a New York limited partnership in which Merrill Lynch Venture Capital Inc. (the "Management Company") is the general partner. The Management Company is an indirect subsidiary of Merrill Lynch & Co., Inc. and an affiliate of Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S"). DLJ Capital Management Corporation (the "Sub-Manager"), an affiliate of Donaldson, Lufkin and Jenrette, Inc., is the sub-manager pursuant to a sub-management agreement, dated May 23, 1991, among the Partnership, the Managing General Partner, the Management Company and the Sub-Manager. The Partnership operates as a business development company under the Investment Company Act of 1940. The Partnership's investment objective is to seek long-term capital appreciation from its portfolio of venture capital investments. The Partnership considers this activity to constitute the single industry segment of venture capital investing. Through MLPF&S, the Partnership publicly offered 120,000 Units at $1,000 per Unit. The Units were registered under the Securities Act of 1933 pursuant to a Registration Statement on Form N-2 (File No. 33-3220) which was declared effective on February 10, 1987. The Partnership held its initial and final closings on March 31, 1987 and June 10, 1987, respectively. A total of 120,000 Units were accepted at such closings and the additional limited partners (the "Limited Partners") were admitted to the Partnership. The information set forth under the captions "Risk and Other Important Factors" (pages 8 through 11), "Investment Objective and Policies" (pages 14 through 16), "Venture Capital Operations" (pages 17 through 20) and "Portfolio Valuation" (pages 27 and 28) in the prospectus of the Partnership dated February 10, 1987, filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as supplemented by a supplement thereto dated April 21, 1987 and filed pursuant to Rule 424(c) under the Securities Act of 1933 (the "Prospectus"), is incorporated herein by reference. The Venture Capital Investments During the year ended December 31, 1994, the Partnership invested $2.4 million in six existing portfolio companies. As of December 31, 1994, the Partnership had invested $113.1 million in 58 portfolio companies. At December 31, 1994, the Partnership's investment portfolio consisted of 28 active investments with a cost of $52.9 million and a fair value of $75.4 million. From its inception through December 31, 1994, the Partnership has fully or partially liquidated investments with an aggregate cost basis of $60.2 million. These liquidated investments returned a total of $69.8 million to the Partnership for a realized gain of $9.6 million. The Partnership also realized interest and dividend income from its venture capital investments totaling $2.4 million from inception to December 31, 1994. The venture capital investments made by the Partnership during 1994 are as follows: The description of the Partnership's follow-on investment in Viasoft, Inc. set forth in Item 5 of Part II of the Partnership's quarterly report on Form 10-Q for the quarter ended March 31, 1994 is incorporated herein by reference. The descriptions of the Partnership's follow-on investments in Photon Dynamics, Inc. and Neocrin Company set forth in Item 5 of Part II of the Partnership's quarterly report on Form 10-Q for the quarter ended June 30, 1994 are incorporated herein by reference. The description of the Partnership's follow-on investment in CellPro, Incorporated set forth in Item 5 of Part II of the Partnership's quarterly report on Form 10-Q for the quarter ended September 30, 1994 are incorporated herein by reference. On October 21, 1994, the Partnership purchased a 9% promissory note of Clarus Medical Systems, Inc. for $136,623 which was equal to the face amount of the note. On December 1, 1994, the Partnership purchased a 9.25% promissory note from Neocrin Company for $311,584 which was equal to the face amount of the note. On December 13, 1994, the Partnership purchased 97,273 common shares of Corporate Express, Inc. from the Management Company for $1.1 million plus interest expense of $42,000. In connection with a transaction in which affiliates of the Sub-Manager also participated, the Management Company had purchased this investment in January 1994 on behalf of the Partnership and held such investment while the Partnership awaited an exemptive order from the Securities and Exchange Commission allowing it to purchase the investment from the Management Company upon review and approval by the Independent General Partners. Competition The Partnership encounters competition from other entities having similar investment objectives, including other entities affiliated with Merrill Lynch & Co., Inc. Primary competition for venture capital investments has been from venture capital partnerships, venture capital affiliates of large industrial and financial companies, small business investment companies and wealthy individuals. Competition has also been from foreign investors and from large industrial and financial companies investing directly rather than through venture capital affiliates. The Partnership has frequently been a co-investor with other professional venture capital groups and these relationships generally have expanded the Partnership's access to investment opportunities. Employees The Partnership has no employees. The Partnership Agreement provides that the Managing General Partner, subject to the supervision of the Individual General Partners, manages and controls the Partnership's venture capital investments. The Management Company performs, or arranges for others to perform, the management and administrative services necessary for the operation of the Partnership and is responsible for managing the Partnership's short-term investments. The Sub-Manager, subject to the supervision of the Management Company and Individual General Partners, provides management services in connection with the Partnership's venture capital investments and investments of the Partnership in unaffiliated venture capital funds. Item 2. Properties. The Partnership does not own or lease physical properties. Item 3. Legal Proceedings. The Partnership has been named as a defendant in an action relating to its ownership of securities of In-Store Advertising, Inc. ("In-Store Advertising"). On or about July 16, 1993, a Second Amended Consolidated Class Action Complaint (the "Amended Complaint") was filed in the United States District Court for the Southern District of New York in the In Re In-Store Advertising Securities Litigation. The action is a purported class action suit wherein the plaintiffs (the "Plaintiffs") are persons who allegedly purchased shares of In-Store Advertising common stock in the July 19, 1990 initial public offering (the "Offering") and through November 8, 1990. The defendants named in the Amended Complaint include present and former individual officers and directors of In-Store Advertising, the underwriters involved in the Offering, KPMG Peat Marwick (In-Store Advertising's auditors) and certain other defendants, including the Partnership, who owned In-Store Advertising securities prior to the Offering (the "Venture Capital Defendants"). Prior to the filing of the Amended Complaint, In-Store Advertising filed a "prepackaged" plan in U.S. Bankruptcy Court pursuant to Chapter XI of the U.S. Bankruptcy Code. The Amended Complaint alleges violations under Sections 11, 12(2) and 15 of the Securities Act of 1933, as amended (the "1933 Act"), Section 10(b) and 20 of the Securities Exchange Act of 1934, as amended (the "1934 Act") and Rule 10b-5 promulgated thereunder, and common law claims of negligent misrepresentation, fraud and deceit in connection with the sale of securities. The Plaintiffs seek rescission of the purchases of In-Store Advertising's common stock to the extent the members of the alleged classes still hold their shares, together with damages and certain costs and expenses. The Amended Complaint alleges that the Venture Capital Defendants are liable under Section 10(b) of the 1934 Act and Rule 10b-5, and are also liable as controlling persons of In-Store Advertising within the meaning of Section 15 of the 1933 Act and Section 20(a) of the 1934 Act. The Venture Capital Defendants are also being sued as alleged knowing and substantial aiders and abettors of the other defendants' wrongful conduct and under common law fraud and negligence theories. An individual director of In-Store Advertising, named as a defendant in the action, was a Vice President of Merrill Lynch Venture Capital Inc., the General Partner of the Managing General Partner of the Partnership. The Partnership believes that it has meritorious defenses to the allegations in the Amended Complaint (see Note 8 of Notes to Financial Statements). Item 4. Submission of Matters to a Vote of Security Holders. No matter was submitted during the fourth quarter of the fiscal year covered by this report to a vote of security holders. The 1995 Annual Meeting of the limited partners of the Partnership is scheduled to be held on May 2, 1995. PART II Item 5. Market for Registrant's Common Equity and Related Stockholder Matters. The information with respect to the market for the Units set forth under the subcaption "Substituted Limited Partners" on pages 30 and 31 of the Prospectus is incorporated herein by reference. There is no established public trading market for the Units as of March 15, 1995. The approximate number of holders of Units as of March 15, 1995 is 13,500. The Managing General Partner and the Individual General Partners of the Partnership also hold interests in the Partnership. Beginning with December 1994 client account statements, Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") implemented new guidelines for valuing limited partnerships and other direct investments reported on client account statements. As a result, MLPF&S no longer reports general partner estimates of limited partnership net asset value on its client account statements, although the Partnership's managing general partner may continue to provide its estimate of net asset value in quarterly reports to unit holders. Pursuant to the new guidelines, estimated values for limited partnership investments will be provided annually to MLPF&S by independent valuation services. The estimated values will be based on financial and other information available to the independent services on the prior August 15th. MLPF&S clients may contact their Merrill Lynch Financial Consultants or telephone the number provided to them on their account statements to obtain a general description of the methodology used by the independent valuation services to determine their estimates of value. The estimated values provided by the independent services are not market values and unit holders may not be able to sell their units or realize the amounts shown on their MLPF&S statements upon a sale. In addition, unit holders may not realize the amount shown on their account statements upon the liquidation of the Registrant over its remaining life. Cash distributions paid to Partners during 1994, 1993 and 1992 and cumulative cash distributions paid from the inception of the Partnership through December 31, 1994 are listed below: Managing Distribution General Limited Per $1,000 Date Partner Partners Unit ---- ------- -------- ---- April 30, 1992 $ 9,000,000 $ 75 May 26, 1993 $ 15,600,000 $ 130 May 26, 1994 $ 16,200,000 $ 135 September 1, 1994 $ 1,400,000 Cumulative totals $ 1,400,000 $ 58,800,000 $ 490
Additionally, on March 1, 1995, the General Partners approved a cash distribution to Partners totaling $11.2 million; $9 million, or $75 per unit, to the Limited Partners and $2.2 million to the Managing General Partner. The distribution will be paid in April 1995 to Limited Partners of record on March 31, 1995 and will bring cumulative cash distributions paid to Limited Partners to $67.8 million, or $565 per $1,000 Unit. Cumulative cash distributions paid to the Managing General Partner will total $3.6 million. Item 6. Selected Financial Data. ($ In Thousands, Except For Per Unit Information) Years Ended December 31, 1994 1993 1992 1991 1990 ---- ---- ---- ---- ---- Net Realized Gain (Loss) on Investments $ 18,593 $ 10,605 $ (5,677) $ 1,968 $ (15,142) Net Change in Unrealized Appreciation of Investments (29,444) 9,430 11,657 14,361 4,525 Net Increase (Decrease) in Net Assets Resulting from Operations (11,668) 18,581 4,809 15,954 (9,976) Cash Distributions to Partners 17,600 15,600 9,000 6,000 - Cumulative Cash Distributions to Partners 60,200 42,600 27,000 18,000 12,000 Net Assets 83,402 112,671 109,690 113,881 103,927 Net Unrealized Appreciation of Investments 22,464 51,908 42,478 30,821 16,460 Purchase of Portfolio Investments 2,428 8,050 13,781 9,845 7,790 Cumulative Cost of Portfolio Investments 113,110 110,682 102,633 88,852 79,006 PER UNIT OF LIMITED PARTNERSHIP INTEREST: Net Realized Gain (Loss) on Investments $ 135 $ 87 $ (47) $ 16 $ (125) Net Increase (Decrease) in Net Assets Resulting from Operations (79) 120 29 104 (65) Cash Distributions 135 130 75 50 - Cumulative Cash Distributions 490 355 225 150 100 Net Unrealized Appreciation of Investments 148 355 310 225 133 Net Asset Value, Including Net Unrealized Appreciation of Investments 638 852 862 908 854
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. Liquidity and Capital Resources During 1994, the Partnership made follow-on investments in six existing portfolio companies totaling $2.4 million and used $1.3 million for operating activities. Also during the year, the Partnership realized a net return of $23.5 million from the sale of certain portfolio investments. During 1994, the Partnership paid cash distributions to Partners totaling $17.6 million. At December 31, 1994, the Partnership held $7.6 million in cash and short-term investments; $6.9 million in short-term securities with maturities of less than one year and $639,000 in an interest-bearing cash account. Funds needed to cover future operating expenses and follow-on investments will be obtained from the Partnership's existing cash reserves, from interest and other investment income and from proceeds received from the sale of portfolio investments. The Partnership does not expect to make any new portfolio investments. Therefore, generally, all cash received from the sale of portfolio investments, after an adequate reserve for operating expenses and follow-on investments in existing portfolio companies, is distributed to Partners as soon as practicable after receipt. Subsequent to the end of the year, the Partnership sold a portion of its common stock holdings in two of its publicly held companies for $6.4 million. As a result, in March 1995, the General Partners approved a cash distribution to Partners of $11.2 million; $9 million, or $75 per unit, to the Limited Partners and $2.2 million to the Managing General Partner. The distribution will be paid in April 1995 to Limited Partners of record on March 31, 1995. After the April 1995 distribution, cumulative cash distributions to Partners will total $71.4 million; $67.8 million, or $565 per unit, to the Limited Partners and $3.6 million to the Managing General Partner. Results of Operations For the years ended December 31, 1994 and 1993, the Partnership had a net realized gain from operations of $17.8 million and $9.2 million, respectively. For the year ended December 31, 1992, the Partnership had a net realized loss from operations of $6.8 million. Net realized gain or loss from operations is comprised of 1) net realized gains or losses from portfolio investments and 2) net investment income or loss (interest and dividend income less operating expenses). Realized Gains and Losses from Portfolio Investments - For the year ended December 31, 1994, the Partnership had an $18.6 million net realized gain from portfolio investments. During 1994, the Partnership sold a portion of its common stock holdings in eight of its publicly held investments for $20.2 million, realizing a gain of $17.5 million. The number of common shares sold of each portfolio company were as follows: 55,336 shares of Borg-Warner Automotive, Inc., 79,232 shares of Corporate Express, Inc., 382,000 shares of CellPro, Incorporated, 140,000 shares of Regeneron Pharmaceuticals, Inc., 78,271 shares of Ringer Corporation, 106,666 shares of Micro Linear Corporation, 90,000 shares of Komag, Incorporated and 2,400 shares of MTI Technology Corporation. Additionally, in two private transactions completed during 1994, the Partnership sold its 94,435 preferred shares of The Business Depot Ltd. for $2.8 million, realizing a gain of $1.5 million and sold 26,570 preferred shares of OccuSystems, Inc. for $173,000, realizing a gain of $40,000. Also during 1994, the Partnership wrote-off its $100,000 investment in Research Applications, Inc. and sold its investment in Shared Resource Exchange, Inc., realizing a loss of $250,000. The Partnership also wrote-off the cost of its warrant to purchase 380,000 common shares of IDEC Pharmaceuticals Corporation, which expired in February 1995, realizing a loss of $217,000. The Partnership also realized gains in 1994 totaling $54,000 from the receipt of final escrow payments relating to the 1992 sale of its investment in R-Byte, Inc. For the year ended December 31, 1993, the Partnership had a $10.6 million net realized gain from portfolio investments. During 1993, the Partnership sold 525,000 common shares of Regeneron Pharmaceuticals in the public market, realizing a gain of $7.6 million. The Partnership also sold 187,912 common shares of Ringer in the public market, realizing a gain of $4,000. In January 1993, the Partnership sold its investment in Pyxis Corporation in a private transaction, realizing a gain of $7.2 million. Also during 1993, In-Store Advertising, Inc. ("ISA") filed for protection under Chapter 11 of the federal Bankruptcy Code resulting in the write-off of the Partnership's remaining $1.1 million investment in the company. The Partnership also received a final liquidation payment from InteLock Corporation resulting in a $123,000 realized loss, wrote-off its $2 million investment in Ogle Resources, Inc. and wrote-off the remaining $900,000 of its investment in Communications International, Inc. ("CII"). Several smaller portfolio transactions completed during the year resulted in an additional $46,000 net realized loss for 1993. For the year ended December 31, 1992, the Partnership had a $5.7 million net realized loss from portfolio investments. During the year, the Partnership sold its remaining 157,500 common shares of Everex Systems, Inc. in the public market, realizing a gain of $371,000. The Partnership also sold 45,000 common shares of Regeneron Pharmaceuticals in the public market, realizing a gain of $575,000. In September 1992, the Partnership received 50,111 shares of Bolt Beranek and Newman Inc. common stock in connection with the termination of BBN Integrated Switch Partners, L.P. These shares were sold in the public market in October and November 1992 for $200,000, resulting in a realized gain of $13,000. In May 1992, Allez, Inc. filed for protection under Chapter 11 of the federal Bankruptcy Code. As a result, the Partnership wrote-off its $1.8 million investment in the company. In October 1992, the Partnership sold its investment in R-Byte to Exabyte Corporation for $1.3 million, resulting in a realized loss of $444,000. The Partnership also wrote-off the following investments; $1.1 million of its $1.3 million investment in InteLock, $1.1 million of its $2.3 million investment in ISA, $919,000 of its $1.8 million investment in CII, $1.1 million of its $1.5 million investment in Target Vision, Inc. and $102,000 of its remaining investment in TCOM Systems, Inc. due to continued operational and financial difficulties at these companies. Investment Income and Expenses - For the years ended December 31, 1994, 1993 and 1992, the Partnership had a net investment loss of $817,000, $1.5 million and $1.2 million, respectively. The decrease in net investment loss for the 1994 period compared to the 1993 period primarily is attributable to a $682,000 increase in interest and other income from portfolio investments for the 1994 period. This increase primarily was a result of dividends received from Borg-Warner Automotive, Inc., which began during 1994. Additionally, other income from portfolio investments for 1993 includes the write-off of $406,000 of accrued interest receivable related to promissory notes due from Ogle Resources that were written-off in 1993. Expenses increased $56,000 for 1994 compared to 1993, primarily resulting from a $142,000 increase in professional fees for the 1994 period primarily relating to legal fees incurred from the ISA litigation (see Note 8 of Notes to Financial Statements). The Partnership also incurred $42,000 of interest expense during 1994 in connection with its purchase of 97,273 shares of Corporate Express, Inc. from the Management Company (see Note 4 of Notes to Financial Statements). The $142,000 increase in professional fees was offset by a $112,000 decrease in the management fee for the 1994 period, as discussed below. The increase in net investment loss for the 1993 period compared to the 1992 period is attributable to a reduction in investment income earned in 1993, specifically interest income earned from the Partnership's short-term investments and the write-off, during 1993, of $406,000 of accrued interest receivable related to the Partnership's promissory note due from Ogle, as previously discussed. The reduction in investment income was partially offset by a decrease in the 1993 management fee, as discussed below. Interest earned from short-term investments for the years ended December 31, 1993 and 1992 was $360,000 and $805,000, respectively. The decrease for the 1993 period compared to the 1992 period primarily is due to a reduction in funds invested in short-term investments and declining interest rates during the 1993 period. The Management Company performs, or arranges for others to perform, the management and administrative services necessary for the operation of the Partnership. The Management Company receives a management fee at an annual rate of 2.5% of the gross capital contributions to the Partnership, reduced by selling commissions, organizational and offering expenses paid by the Partnership, return of capital and realized capital losses, with a minimum annual fee of $200,000. Such fee is determined and payable quarterly. The management fee for the years ended December 31, 1994, 1993 and 1992, was $1.3 million, $1.4 million and $1.7 million, respectively. The management fee will continue to decline in future periods as the Partnership's investment portfolio continues to mature and distributions are paid to Partners. The management fee and other operating expenses are paid with funds provided from operations. Funds provided from operations for the periods discussed were obtained from interest received from short-term investments, interest and other income from portfolio investments and proceeds from the sale of certain portfolio investments. Unrealized Gains and Losses and Changes in Unrealized Appreciation or Depreciation of Portfolio Investments - For the year ended December 31, 1994, the Partnership had a $14.4 million net unrealized loss from its portfolio investments, primarily resulting from the net downward revaluation of its publicly traded securities. Additionally during 1994, a net $15 million was transferred from unrealized gain to realized gain relating to portfolio investments sold and written-off during 1994, as discussed above. The $15 million transfer from unrealized gain to realized gain combined with the $14.4 million unrealized loss, resulted in a $29.4 million reduction to the Partnership's net unrealized appreciation of investments for 1994. For the year ended December 31, 1993, the Partnership had a $20.8 million unrealized gain resulting from the net upward revaluation of its portfolio investments, primarily Regeneron, Corporate Express and CellPro. Additionally during 1993, a net $11.4 million was transferred from unrealized gain to realized gain relating to portfolio investments sold and written-off during 1993, as discussed above. The $20.8 million unrealized gain, offset by the $11.4 million net transfer from unrealized gain to realized gain, resulted in a $9.4 million increase to the Partnership's net unrealized appreciation of investments for 1993. For the year ended December 31, 1992, the Partnership had a $6.8 million unrealized gain resulting from the net upward revaluation of certain portfolio investments, primarily Pyxis and CellPro. Additionally during 1992, a net $4.9 million was transferred from unrealized loss to realized loss relating to portfolio investments sold and written-off during 1992, as discussed above. The $6.8 million unrealized gain combined with the $4.9 million transfer from unrealized loss to realized loss resulted in an $11.7 million increase to the Partnership's net unrealized appreciation of investments for 1992. Net Assets - Changes to net assets resulting from operations is comprised of 1) net realized gains and losses from operations and 2) changes to net unrealized appreciation or depreciation of portfolio investments. For the year ended December 31, 1994, the Partnership had an $11.7 million net decrease in net assets resulting from operations comprised of the $29.4 million decline in unrealized appreciation offset by the $17.8 million net realized gain from operations for 1994. At December 31, 1994, the Partnership's net assets were $83.4 million, down $29.3 million from $112.7 million at December 31, 1993. This decrease resulted from the $11.7 million decrease in net assets from operations for 1994 and the $17.6 million cash distribution paid to Partners in 1994. For the year ended December 31, 1993, the Partnership had an $18.6 million net increase in net assets resulting from operations comprised of the $9.2 million net realized gain from operations and the $9.4 million increase in unrealized appreciation for 1993. At December 31, 1993, the Partnership's net assets were $112.7 million, up $3 million from $109.7 million at December 31, 1992. This increase resulted from the $18.6 million net increase in net assets from operations offset by the $15.6 million cash distribution to Limited Partners paid during 1993. For the year ended December 31, 1992, the Partnership had a net increase in net assets resulting from operations of $4.8 million comprised of the $11.7 million increase in unrealized appreciation offset by the $6.8 million net realized loss from operations for 1992. At December 31, 1992, the Partnership's net assets were $109.7 million, down $4.2 million from $113.9 million at December 31, 1991. This decrease resulted from the $9 million cash distribution paid to Limited Partners during 1992 offset by the $4.8 million increase in net assets from operations for 1992. Gains and losses from investments are allocated to Partners' capital accounts when realized, in accordance with the Partnership Agreement (see Note 3 of Notes to Financial Statements). However, for purposes of calculating the net asset value per unit of limited partnership interest, net unrealized appreciation of investments has been included as if the net appreciation had been realized and allocated to the Limited Partners in accordance with the Partnership Agreement. Pursuant to such calculation, the net asset value per $1,000 Unit at December 31, 1994, 1993 and 1992, was $638, $852 and $862, respectively. Item 8. Financial Statements and Supplementary Data. ML VENTURE PARTNERS II, L.P. INDEX Independent Auditors' Report Balance Sheets as of December 31, 1994 and 1993 Schedule of Portfolio Investments as of December 31, 1994 Schedule of Portfolio Investments as of December 31, 1993 Statements of Operations for the years ended December 31, 1994, 1993 and 1992 Statements of Cash Flows for the years ended December 31, 1994, 1993 and 1992 Statements of Changes in Partners' Capital for the years ended December 31, 1994, 1993 and 1992 Notes to Financial Statements NOTE - All other schedules are omitted because of the absence of conditions under which they are required or because the required information is included in the financial statements or the notes thereto. INDEPENDENT AUDITORS' REPORT ML Venture Partners II, L.P.: We have audited the accompanying balance sheets of ML Venture Partners II, L.P. (the "Partnership"), including the schedules of portfolio investments, as of December 31, 1994 and 1993, and the related statements of operations, cash flows, and changes in partners' capital for each of the three years in the period ended December 31, 1994. These financial statements are the responsibility of the Partnership's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned at December 31, 1994 and 1993 by correspondence with the custodian; where confirmation was not possible, we performed other audit procedures. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, such financial statements present fairly, in all material respects, the financial position of ML Venture Partners II, L.P. at December 31, 1994 and 1993, and the results of its operations, its cash flows and the changes in its partners' capital for each of the three years in the period ended December 31, 1994 in conformity with generally accepted accounting principles. As explained in Note 2, the financial statements include securities valued at $70,024,107 and $107,038,636 at December 31, 1994 and 1993, respectively, representing 84% and 95% of net assets, respectively, whose values have been estimated by the Managing General Partner in the absence of readily ascertainable market values. We have reviewed the procedures used by the Managing General Partner in arriving at its estimate of value of such securities and have inspected underlying documentation, and, in the circumstances, we believe the procedures are reasonable and the documentation appropriate. However, because of the inherent uncertainty of valuation, those estimated values may differ significantly from the values that would have been used had a ready market for the securities existed, and the differences could be material. As discussed in Note 8 to the financial statements, the Partnership is a defendant in litigation relating to the Partnership's ownership of securities of In-Store Advertising, Inc. The ultimate outcome of the litigation cannot presently be determined. Accordingly, no provision for any loss that may result upon resolution of this matter has been made in the accompanying financial statements. Deloitte & Touche LLP New York, New York February 24, 1995, except for Note 7, as to which the date is March 1, 1995 ML VENTURE PARTNERS II, L.P. BALANCE SHEETS December 31, 1994 1993 ---- ---- ASSETS Investments - Note 2 Portfolio investments, at fair value (cost $52,936,366 at December 31, 1994 and $55,130,444 at December 31, 1993) $ 75,400,208 $ 107,038,636 Short-term investments, at amortized cost - Note 9 6,935,099 3,991,697 Cash and cash equivalents 638,868 1,412,882 Accrued interest receivable 563,815 220,067 Notes receivable 250,656 102,579 Receivable from securities sold 7,655 321,300 ----- ------- TOTAL ASSETS $ 83,796,301 $ 113,087,161 = ========== = =========== LIABILITIES AND PARTNERS' CAPITAL Liabilities: Accounts payable $ 43,472 $ 41,535 Due to Management Company - Note 4 325,000 353,242 Due to Independent General Partners - Note 5 25,350 21,450 ------ ------ Total liabilities 393,822 416,227 ------- ------- Partners' Capital: Managing General Partner 2,191,479 1,033,457 Individual General Partners 3,917 3,410 Limited Partners (120,000 Units) 58,743,241 59,725,875 Unallocated net unrealized appreciation of investments - Note 2 22,463,842 51,908,192 ---------- ---------- Total partners' capital 83,402,479 112,670,934 ---------- ----------- TOTAL LIABILITIES AND PARTNERS' CAPITAL $ 83,796,301 $ 113,087,161 = ========== = ===========
See notes to financial statements. ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS December 31, 1994 Active Portfolio Investments: Initial Investment Company / Position Date Cost Fair Value Biocircuits Corporation*(A) 515,269 shares of Common Stock May 1991 $ 1,422,501 $ 230,428 - ------------------------------ -------- - --------- - ------- Borg-Warner Automotive, Inc.*(A)(B) 444,664 shares of Common Stock Sept. 1988 2,223,320 8,254,075 - ------------------------------ ---------- --------- --------- Borg-Warner Security Corporation*(A) 500,000 shares of Common Stock Sept. 1988 2,500,000 3,440,625 - ------------------------------ ---------- --------- --------- CellPro, Incorporated(A)(C) 411,333 shares of Common Stock Mar. 1989 764,525 4,641,379 - ------------------------------ --------- ------- --------- Children's Discovery Centers of America, Inc.(A) 115,267 shares of Common Stock July 1988 2,000,259 1,163,240 - ------------------------------ --------- --------- --------- Clarus Medical Systems, Inc.* 507,458 shares of Preferred Stock Jan. 1991 2,037,290 571,357 9% Promissory Note due 3/21/95 136,623 136,623 Warrants to purchase 20,238 shares of Common Stock at $3.75 per share, expiring on 7/31/97 0 0 --------------------------------------- - - Corporate Express, Inc.*(A)(D) 696,234 shares of Common Stock May 1992 2,964,258 9,263,998 - ------------------------------ -------- --------- --------- Diatech, Inc.* 1,258,006 shares of Preferred Stock Dec. 1991 2,620,015 3,145,015 - ----------------------------------- --------- --------- --------- Eckerd Corporation*(A) 92,843 shares of Common Stock July 1992 857,004 2,031,521 - ----------------------------- --------- ------- --------- Elantec, Inc. 2,889,947 shares of Preferred Stock Aug. 1988 1,069,569 1,069,569 852,273 shares of Common Stock 340,909 340,909 - ------------------------------ ------- ------- Home Express, Inc.* 486,067 shares of Preferred Stock June 1992 1,822,751 2,303,957 - --------------------------------- --------- --------- --------- Horizon Cellular Telephone Company, L.P.: HCTC Investment, L.P. 10% Promissory Note due 3/26/98 May 1992 2,587,500 2,587,500 SPTHOR Corporation 10% Promissory Note due 3/26/98 May 1992 646,875 646,875 34.5 shares of Common Stock 215,625 215,625 --------------------------- ------- ------- I.D.E. Corporation* 493,391 shares of Preferred Stock Mar. 1988 1,110,909 555,455 - --------------------------------- --------- --------- ------- IDEC Pharmaceuticals Corporation(A)(E): ML/MS Associates, L.P.* 34.4% Limited Partnership interest June 1989 3,960,000 3,960,000 MLMS Cancer Research, Inc. 400,000 shares of Common Stock July 1989 46,957 46,957 ------------------------------ --------- ------ ------
ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS December 31, 1994 Initial Investment Company / Position Date Cost Fair Value Inference Corporation 702,427 shares of Preferred Stock Apr. 1993 $ 785,032 $ 785,032 Warrants to purchase 193,682 shares of Preferred Stock at $1 per share, expiring on 4/19/99 22,777 22,777 Warrants to purchase 24,233 shares of Preferred Stock at $1.05 per share, expiring on 12/16/97 6,531 6,531 Warrants to purchase 295,827 shares of Common Stock at $1 per share, expiring on 6/10/98 79,725 79,725 ------------------------------------ ------ ------ Komag, Incorporated(A)(F) 144,486 shares of Common Stock Aug. 1988 1,331,561 3,731,351 - ------------------------------ --------- --------- --------- Ligand Pharmaceuticals Inc.*(A)(G) 499,858 shares of Common Stock Apr. 1989 1,216,466 2,615,507 Warrants to purchase 5,584 shares of Common Stock at $3.61 per share to $9.60 per share, expiring between 1/18/96 and 7/31/97 0 2,415 ------------------- - ----- Micro Linear Corporation(A)(H) 213,419 shares of Common Stock Aug. 1988 746,969 1,033,482 - ------------------------------ --------- ------- --------- Neocrin Company(I) 317,366 shares of Preferred Stock June 1991 3,369,046 1,586,830 9.25% Convertible Notes due 6/22/95 629,176 629,176 - ----------------------------------- ------- ------- OccuSystems, Inc.(J) 504,830 shares of Preferred Stock June 1993 2,524,150 3,155,188 - --------------------------------- --------- --------- --------- Photon Dynamics, Inc.* 1,222,828 shares of Preferred Stock Sept. 1988 2,452,226 1,435,181 - ----------------------------------- ---------- --------- --------- Raytel Medical Corporation* 1,000,000 shares of Preferred Stock Feb. 1990 1,000,000 2,000,000 Options to purchase 55,938 shares of Preferred Stock at $.71 per share, expiring 10/31/01 0 72,160 ------------------------------------ - ------ Regeneron Pharmaceuticals, Inc.(A)(K) 1,377,895 shares of Common Stock Jan. 1988 1,616,740 3,883,919 - -------------------------------- --------- --------- --------- Sanderling Biomedical, L.P.*(L) 80% Limited Partnership interest May 1988 2,000,000 1,790,799 - -------------------------------- -------- --------- --------- SDL, Inc.*(M) 8% Subordinated Note due 7/17/97 July 1992 2,019,721 2,019,721 97,011 shares of Common Stock 169,769 1,361,064 26,270 shares of Preferred Stock 849,834 849,834 - -------------------------------- ------- ------- Target Vision, Inc.* 395,000 shares of Preferred Stock Apr. 1987 395,000 0 - --------------------------------- --------- ------- -
ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS December 31, 1994 Initial Investment Company / Position Date Cost Fair Value United States Paging Corporation*(A)(N) 450,053 shares of Common Stock Apr. 1987 $ 1,479,405 $ 2,146,618 Warrants to purchase 16,887 shares of Common Stock at $3.33 per share, expiring between 2/27/95 and 4/28/95 0 24,308 Warrants to purchase 25,330 shares of Common Stock at $.89 per share, expiring between 12/15/95 and 3/8/96 0 98,277 ---------------------------------------------------- - ------ Viasoft, Inc.(O) 861,885 shares of Preferred Stock Dec. 1987 915,348 1,465,205 - --------------------------------- --------- ------- --------- Totals from Active Portfolio Investments $ 52,936,366 $ 75,400,208 - ---------- - ----------
Supplemental Information: Liquidated Portfolio Investments(Q) Liquidation Realized Company Date Cost Gain (Loss) Return Allez, Inc. 1992 $ 1,781,320 $ (1,781,320) $ 0 Amdahl Corporation 1989 729,742 1,837,787 2,567,529 Aqua Group, Inc. 1990 2,000,000 (1,999,999) 1 BBN Advanced Computer Partners, L.P. 1990 868,428 (864,028) 4,400 BBN Integrated Switch Partners, L.P. 1990/1992 5,022,380 (4,822,797) 199,583 Borg-Warner Automotive, Inc.(B) 1994 276,680 928,538 1,205,218 Business Depot, Ltd.(P) 1994 1,214,184 1,539,475 2,753,659 CellPro, Incorporated(C) 1994 796,419 10,742,300 11,538,719 Communications International, Inc. 1992-1994 1,819,332 (1,819,331) 1 Computer-Aided Design Group 1990/1991 1,131,070 (1,131,069) 1 Corporate Express, Inc.(D) 1994 35,653 1,588,600 1,624,253 Data Recording Systems, Inc. 1988 1,615,129 (1,499,999) 115,130 Elantec, Inc. 1993 1,640 (1,640) 0 Everex Systems, Inc. 1991/1992 750,000 447,606 1,197,606 Hoffman & Company, L.P. 1993 40,000 (40,000) 0 IDEC Pharmaceuticals Corporation(E) 1994 217,391 (217,391) 0 In-Store Advertising, Inc. 1992 2,259,741 (2,259,741) 0 InteLock Corporation 1992 1,254,125 (1,251,274) 2,851
ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS - continued December 31, 1994 Liquidation Realized Company Date Cost Gain (Loss) Return Komag, Incorporated(F) 1991/1994 $ 1,033,676 $ 1,605,568 $ 2,639,244 Ligand Pharmaceuticals Inc. 1992 187,250 0 187,250 Magnesys 1989 1,440,997 (1,412,049) 28,948 Meteor Message Corporation 1990 1,501,048 (1,501,047) 1 Micro Linear Corporation(H) 1994 373,331 469,330 842,661 OccuSystems, Inc.(J) 1994 132,850 39,855 172,705 Ogle Resources, Inc. 1993 1,974,286 (1,974,186) 100 Pandora Industries, Inc. 1990 2,060,139 (2,060,138) 1 Pyxis Corporation 1993 634,598 7,169,424 7,804,022 R-Byte Inc. 1992-1994 1,991,098 (443,566) 1,547,532 Regeneron Pharmaceuticals, Inc.(K) 1991-1994 1,061,395 19,317,755 20,379,150 Research Applications, Inc.(P) 1994 100,000 (100,000) 0 Ringer Corporation(P) 1991-1994 3,029,652 (2,208,012) 821,640 S & J Industries 1991/1992 1,600,150 (1,555,149) 45,001 Saxpy Computer Corporation 1988 2,000,000 (2,000,000) 0 SDL, Inc. 1993 1,717,941 0 1,717,941 SF2 Corporation 1991-1994 2,193,293 (1,856,570) 336,723 Shared Resource Exchange, Inc.(P) 1990-1994 999,999 (999,998) 1 Special Situations, Inc. 1988 215,000 (187,175) 27,825 Storage Technology Corporation 1990 2,174,000 1,466,802 3,640,802 Target Vision, Inc. 1992 1,105,000 (1,105,000) 0 TCOM Systems, Inc. 1990/1992 4,715,384 (4,711,536) 3,848 Telecom USA, Inc. 1989 5,000,000 3,361,778 8,361,778 Touch Communications Incorporated 1991 1,119,693 (1,119,693) 0 Totals from Liquidated Portfolio Investments $ 60,174,014 $ 9,592,110 $ 69,766,124 = ========== = ========= = ========== Combined Net Combined Unrealized and Fair Value Cost Realized Gain and Return Totals from Active & Liquidated Portfolio Investments $ 113,110,380 $ 32,055,952 $ 145,166,332 = =========== = ========== = ===========
ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS - continued December 31, 1994 (A) Public company (B) On October 6, 1994, Borg-Warner Automotive, Inc. completed a public offering of its common stock. In connection with the offering, the Partnership sold 55,336 shares of common stock for $1.2 million, realizing a gain of $929,000. (C) During 1994, the Partnership purchased 10,000 shares of CellPro, Incorporated through the exercise of options received by the Partnership during 1994. Additionally, during 1994, the Partnership sold 382,000 common shares of CellPro for $11.5 million, realizing a gain of $10.7 million. (D) On September 23, 1994, Corporate Express, Inc. completed its initial public offering of common stock. In connection with the offering and a one-for-two reverse split of the company's common stock, the Partnership exchanged its 914,250 preferred shares and 442,136 common shares for 678,193 common shares of the company. In November 1994, the Partnership acquired an additional 97,273 common shares of Corporate Express from the Management Company. Finally, during November 1994, the Partnership sold 79,232 common shares of Corporate Express for $1.62 million, realizing a gain of $1.59 million. (E) On December 31, 1994, the Partnership wrote-off the cost of its warrants to purchase 380,000 shares of IDEC Pharmaceuticals Corporation common stock at $7.25 per share, realizing a loss of $217,000. Such warrants expired in February 1995. (F) During 1994, the Partnership sold 90,000 common shares of Komag Incorporated for $2.4 million, realizing a gain of $1.6 million. Additionally, in January 1995, the Partnership sold 104,486 shares of Komag for $3.0 million, realizing a gain of $2.1 million. (G) During November 1994, Ligand Pharmaceuticals Inc. converted its Class A common stock and warrants into Class B common stock and warrants at a ratio of 1.33 to 1. As a result, the Partnership exchanged its 115,440 Class A common shares and 1,290 Class A common warrants for 153,535 Class B shares and 1,716 Class B warrants. (H) On October 13, 1994, Micro Linear Corporation completed its initial public offering of common stock. In connection with the offering, the company effected a 1-for-2.5 reverse split of its outstanding stock. As a result, the Partnership exchanged its 800,214 common shares for 320,085 common shares of the company. Additionally, the Partnership sold 106,666 shares in the offering for $843,000, realizing a gain of $469,000. (I) During 1994, Neocrin Company effected a one-for-five reverse split of its common and preferred stock. As a result, the Partnership exchanged its 1,586,831 preferred shares for 317,366 preferred shares of the company. (J) During June 1994, the Partnership sold 26,570 preferred shares of OccuSystems, Inc. for $173,000, realizing a gain of $40,000. ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS - continued December 31, 1994 (K) During January 1994, the Partnership sold 140,000 common shares of Regeneron Pharmaceuticals, Inc. for $2.3 million, realizing a gain of $2.2 million. In January and February 1995, the Partnership sold 510,000 common shares of Regeneron for $3.3 million, realizing a gain of $2.8 million. (L) Indirectly, the Partnership has an additional investment in Regeneron Pharmaceuticals, Inc. through its 80% limited partnership interest in Sanderling Biomedical, L.P. (M) In December 1994, SDL, Inc. filed a registration statement for an initial public offering of its common stock at a range of $12 to $14 per share. Adjusted for a proposed conversion of preferred stock into common stock and a 3.4-for-1 split, the Partnership would own 419,155 shares of common stock of SDL upon completion of the offering. (N) On February 17, 1995, United States Paging Corporation merged with Mobile Telecommunications Technologies Corporation ("MTEL"). In connection with the merger, the Partnership exchanged its U.S. Paging holdings for 204,292 shares of MTEL common stock. (O) In February 1995, Viasoft, Inc. filed a registration statement for an initial public offering of its common stock at a range of $7 to $9 per share. Adjusted for a proposed 1-for-3 reverse split, the Partnership would own 287,295 shares of Viasoft common stock upon completion of the offering. (P) In September 1994, the Partnership sold its $1.2 million investment in preferred stock of The Business Depot Ltd. for $2.8 million, realizing a gain of $1.5 million. Additionally, during 1994, the Partnership wrote-off its $100,000 investment in Research Applications, Inc., sold its remaining 78,271 shares of Ringer Corporation common stock for $254,000, realizing a gain of $20,000 and sold its investment in Shared Resource Exchange, Inc., realizing a loss of $250,000. (Q) Amounts provided for "Supplemental Information: Liquidated Portfolio Investments" are cumulative from inception through December 31, 1994. * Company may be deemed an affiliated person of the Partnership as such term is defined in the Investment Company Act of 1940. See notes to financial statements. ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS December 31, 1993 Active Portfolio Investments: Initial Investment Company / Position Date Cost Fair Value Biocircuits Corporation*(A) 515,269 shares of Common Stock May 1991 $ 1,422,501 $ 1,356,446 - ------------------------------ -------- - --------- - --------- Borg-Warner Automotive, Inc.*(A) 500,000 shares of Common Stock Sept. 1988 2,500,000 9,485,000 - ------------------------------ ---------- --------- --------- Borg-Warner Security Corporation*(A) 500,000 shares of Common Stock Sept. 1988 2,500,000 7,584,375 - ------------------------------ ---------- --------- --------- CellPro, Incorporated*(A) 783,333 shares of Common Stock Mar. 1989 1,455,944 19,417,868 - ------------------------------ --------- --------- ---------- Children's Discovery Centers of America, Inc.*(A) 115,267 shares of Common Stock July 1988 2,000,259 920,695 - ------------------------------ --------- --------- ------- Clarus Medical Systems, Inc.* 507,458 shares of Preferred Stock Jan. 1991 2,037,290 807,350 Warrants to purchase 20,238 shares of Common Stock at $3.75 per share, expiring on 7/31/97 0 0 --------------------------------------- - - Corporate Express, Inc.* 442,136 shares of Common Stock May 1992 99,478 2,431,748 914,250 shares of Preferred Stock 1,830,435 5,028,375 - --------------------------------- --------- --------- Diatech, Inc.* 1,258,006 shares of Preferred Stock Dec. 1991 2,620,015 3,145,015 - ----------------------------------- --------- --------- --------- Eckerd Corporation*(A) 92,843 shares of Common Stock July 1992 857,004 1,156,824 - ----------------------------- --------- ------- --------- Elantec, Inc. 2,889,947 shares of Preferred Stock Aug. 1988 1,069,569 1,069,569 852,273 shares of Common Stock 340,909 340,909 - ------------------------------ ------- ------- Home Express, Inc.* 486,067 shares of Preferred Stock Jan. 1992 1,822,751 1,822,751 - --------------------------------- --------- --------- --------- Horizon Cellular Telephone Company, L.P.: HCTC Investment, L.P. 10% Promissory Note May 1992 2,587,500 2,587,500 SPTHOR Corporation 10% Promissory Note May 1992 646,875 646,875 34.5 shares of Common Stock 215,625 215,625 --------------------------- ------- ------- I.D.E. Corporation* 493,391 shares of Preferred Stock Mar. 1988 1,110,909 555,455 - --------------------------------- --------- --------- -------
ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS December 31, 1993 Initial Investment Company / Position Date Cost Fair Value IDEC Pharmaceuticals Corporation(A): ML/MS Associates, L.P.* 34.4% Limited Partnership interest June 1989 $ 3,960,000 $ 3,960,000 Warrants to purchase 380,000 shares of Common Stock of IDEC Pharmaceuticals Corporation at $7.25 per share, expiring on 2/17/95 217,391 0 MLMS Cancer Research, Inc. 400,000 shares of Common Stock July 1989 46,957 46,957 ------------------------------ --------- ------ ------ Inference Corporation 702,427 shares of Preferred Stock Apr. 1993 785,032 785,032 Warrants to purchase 193,682 shares of Preferred Stock at $1 per share, expiring on 4/19/99 22,777 22,777 Warrants to purchase 24,233 shares of Preferred Stock at $1.05 per share, expiring on 12/16/97 6,531 6,531 Warrants to purchase 295,827 shares of Common Stock at $1 per share, expiring on 6/10/98 79,725 79,725 ------------------------------------ ------ ------ Komag, Incorporated(A) 234,486 shares of Common Stock Aug. 1988 2,160,987 3,724,810 - ------------------------------ --------- --------- --------- Ligand Pharmaceuticals Inc.*(A) 115,440 shares of Class A Common Stock Apr. 1989 304,116 872,293 346,323 shares of Class B Common Stock 912,350 1,477,346 Warrants to purchase 5,158 shares of Common Stock at $4.80 per share, expiring between 1/18/96 and 7/31/97 0 3,556 ----------------------------------------------------- - ----- Micro Linear Corporation 800,214 shares of Common Stock Aug. 1988 1,120,300 960,257 - ------------------------------ --------- --------- ------- Neocrin Company 1,586,831 shares of Preferred Stock June 1991 3,369,046 2,102,381 - ----------------------------------- --------- --------- --------- OccuSystems, Inc. 531,400 shares of Preferred Stock June 1993 2,657,000 2,657,000 - --------------------------------- --------- --------- --------- Photon Dynamics, Inc.* 990,530 shares of Preferred Stock Sept. 1988 2,034,090 990,530 - --------------------------------- ---------- --------- ------- Raytel Medical Corporation* 1,000,000 shares of Preferred Stock Feb. 1990 1,000,000 1,000,000 - ----------------------------------- --------- --------- --------- Regeneron Pharmaceuticals, Inc.*(A) 1,517,895 shares of Common Stock Jan. 1988 1,778,052 19,577,845 - -------------------------------- --------- --------- ---------- Research Applications, Inc.* 4,000 shares of Common Stock Apr. 1988 100,000 0 - ---------------------------- --------- ------- - Ringer Corporation(A) 78,271 shares Common Stock Apr. 1987 234,813 254,381 - -------------------------- --------- ------- -------
ML VENTURE PARTNERS II, L.P. SCHEDULE OF PORTFOLIO INVESTMENTS December 31, 1993 Initial Investment Company / Position Date Cost Fair Value Sanderling Biomedical, L.P.* 80% Limited Partnership interest May 1988 $ 2,000,000 $ 2,833,665 - -------------------------------- -------- - --------- - --------- Shared Resource Exchange, Inc. 2,777 shares of Common Stock Apr. 1987 250,000 0 - ---------------------------- --------- ------- - SDL, Inc.* 8% Subordinated Note July 1992 2,019,721 2,019,721 97,011 shares of Common Stock 169,769 169,769 26,270 shares of Preferred Stock 849,834 849,834 - -------------------------------- ------- ------- Target Vision, Inc.* 395,000 shares of Preferred Stock Apr. 1987 395,000 0 - --------------------------------- --------- ------- - The Business Depot Ltd.* 94,435 shares of Preferred Stock May 1992 1,214,184 1,214,184 - -------------------------------- -------- --------- --------- United States Paging Corporation*(A) 450,053 shares of Common Stock Apr. 1987 1,479,405 1,446,290 Warrants to purchase 16,887 shares of Common Stock at $3.33 per share, expiring between 2/27/95 and 4/28/95 0 0 Warrants to purchase 5,537 shares of Common Stock at 4.22 per share, expiring on 6/23/94 0 0 Warrants to purchase 25,330 shares of Common Stock at $.89 per share, expiring between 12/15/95 and 3/8/96 0 40,072 ---------------------------------------------------- - ------ Viasoft, Inc. 806,647 shares of Preferred Stock Dec. 1987 846,300 1,371,300 - --------------------------------- --------- ------- --------- Totals From Active Portfolio Investments $ 55,130,444 $ 107,038,636 = ========== = =========== Cost Realized Loss Return Totals from Liquidated Portfolio Investments $ 55,551,955 $ (9,000,711) $ 46,551,244 = ========== = =========== = ========== Combined Net Combined Unrealized and Fair Value Cost Realized Gain and Return Totals from Active & Liquidated Portfolio Investments $ 110,682,399 $ 42,907,481 $ 153,589,880 = =========== = ========== = ===========
(A) Public company (B) Amounts provided for "Supplemental Information: Liquidated Portfolio Investments" are cumulative from inception through December 31, 1993. * Company may be deemed an affiliated person of the Partnership as such term is defined in the Investment Company Act of 1940. See notes to financial statements. ML VENTURE PARTNERS II, L.P. STATEMENTS OF OPERATIONS For the Years Ended December 31, 1994 1993 1992 ---- ---- ---- INVESTMENT INCOME AND EXPENSES Interest from short-term investments $ 372,789 $ 360,441 $ 805,138 Interest and other income from portfolio investments 537,731 134,921 385,311 Dividend income 279,298 - - ------- ------- ------- Total investment income 1,189,818 495,362 1,190,449 --------- ------- --------- Expenses: Management fee - Note 4 1,333,363 1,444,988 1,680,176 Professional fees 326,655 184,665 233,288 Mailing and printing 197,083 210,561 145,708 Independent General Partners' fees - Note 5 92,584 93,841 102,901 Custodial fees 14,097 14,979 13,833 Consulting fees - - 2,357 Miscellaneous 1,275 1,250 450 Amortization of deferred organizational costs - - 1,509 Interest expense - Note 4 41,687 - 180,521 ------ - ------- Total expenses 2,006,744 1,950,284 2,360,743 --------- --------- --------- NET INVESTMENT LOSS (816,926) (1,454,922) (1,170,294) Net realized gain (loss) from portfolio investments 18,592,821 10,605,019 (5,677,493) ---------- ---------- ---------- NET REALIZED GAIN (LOSS) FROM OPERATIONS (allocable to Partners) - Note 3 17,775,895 9,150,097 (6,847,787) Net change in unrealized appreciation of investments (29,444,350) 9,430,447 11,656,947 ----------- --------- ---------- NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS $ (11,668,455) $ 18,580,544 $ 4,809,160 = =========== = ========== = =========
See notes to financial statements. ML VENTURE PARTNERS II, L.P. STATEMENTS OF CASH FLOWS For the Years Ended December 31, 1994 1993 1992 ---- ---- ---- CASH FLOWS USED FOR OPERATING ACTIVITIES Net investment loss $ (816,926) $ (1,454,922) $ (1,170,294) Adjustments to reconcile net investment loss to cash used for operating activities: (Increase) decrease in receivables and other assets (491,825) 186,164 (201,294) (Increase) decrease in accrued interest on short-term investments (14,089) 14,803 259,633 Decrease in payables (22,405) (42,186) (96,487) Amortization of deferred organizational costs - - 1,509 - - ----- Cash used for operating activities (1,345,245) (1,296,141) (1,206,933) ---------- ---------- ---------- CASH FLOWS PROVIDED FROM INVESTING ACTIVITIES Net return (purchase) of short-term investments (2,929,313) 5,653,777 20,793,496 Cost of portfolio investments purchased (2,427,981) (8,049,501) (13,781,370) Net proceeds from the sale of portfolio investments 23,528,525 16,334,397 3,011,360 Repayment of investments in notes - 2,064,011 431,737 - --------- ------- Cash provided from investing activities 18,171,231 16,002,684 10,455,223 ---------- ---------- ---------- CASH FLOWS FOR FINANCING ACTIVITIES Cash distributions to Partners (17,600,000) (15,600,000) (9,000,000) ----------- ----------- ---------- Increase (decrease) in cash and cash equivalents (774,014) (893,457) 248,290 Cash and cash equivalents at beginning of period 1,412,882 2,306,339 2,058,049 --------- --------- --------- CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 638,868 $ 1,412,882 $ 2,306,339 = ======= = ========= = =========
See notes to financial statements. ML VENTURE PARTNERS II, L.P. STATEMENTS OF CHANGES IN PARTNERS' CAPITAL For the Years Ended December 31, 1992, 1993 and 1994 Unallocated Managing Individual Net Unrealized General General Limited Appreciation of Partner Partners Partners Investments Total Balance at December 31, 1991 $ 1,010,434 $ 3,334 $ 82,046,664 $ 30,820,798 $ 113,881,230 Cash distribution, paid April 30, 1992 - - (9,000,000) - (9,000,000) Net investment loss (11,703) (39) (1,158,552) - (1,170,294) Net realized loss on investments (56,775) (187) (5,620,531) - (5,677,493) Net change in unrealized appreciation of investments - - - 11,656,947 11,656,947 - - - ---------- ---------- Balance at December 31, 1992 941,956 3,108 66,267,581(A) 42,477,745 109,690,390 Cash distribution, paid May 26, 1993 - - (15,600,000) - (15,600,000) Net investment loss (14,549) (48) (1,440,325) - (1,454,922) Net realized gain on investments 106,050 350 10,498,619 - 10,605,019 Net change in unrealized appre- ciation of investments - - - 9,430,447 9,430,447 - - - --------- --------- Balance at December 31, 1993 1,033,457 3,410 59,725,875(A) 51,908,192 112,670,934 Cash distribution, paid May 26, 1994 - - (16,200,000) - (16,200,000) Cash distribution, paid September 1, 1994 (1,400,000) - - - (1,400,000) Net investment loss 153,602 (32) (970,496) - (816,926) Net realized gain on investments 2,404,420 539 16,187,862 - 18,592,821 Net change in unrealized appre- ciation of investments - - - (29,444,350) (29,444,350) - - - ----------- ----------- Balance at December 31, 1994 $ 2,191,479 $ 3,917 $ 58,743,241(A) $ 22,463,842 $ 83,402,479 = ========= = ===== = ========== = ========== = ==========
(A) The net asset value per unit of limited partnership interest, including an assumed allocation of net unrealized appreciation of investments, was $862, $852 and $638 at December 31, 1992, 1993 and 1994, respectively. Cumulative cash distributions paid to Limited Partners from inception to December 31, 1992, 1993 and 1994 totaled $225, $355 and $490 per Unit, respectively. See notes to financial statements. ML VENTURE PARTNERS II, L.P. NOTES TO FINANCIAL STATEMENTS 1. Organization and Purpose ML Venture Partners II, L.P. (the "Partnership") is a Delaware limited partnership formed on February 4, 1986. MLVPII Co., L.P., the managing general partner of the Partnership (the "Managing General Partner") and four individuals (the "Individual General Partners") are the general partners of the Partnership. The general partner of MLVPII Co., L.P. is Merrill Lynch Venture Capital Inc. (the "Management Company"), an indirect subsidiary of Merrill Lynch & Co., Inc. The Partnership's objective is to achieve long-term capital appreciation from its portfolio of venture capital investments in new and developing companies and other special investment situations. The Partnership does not engage in any other business or activity. The Partnership is scheduled to terminate on December 31, 1997. However, pursuant to the Partnership Agreement, the Individual General Partners can extend the termination date for up to two additional two-year periods if they determine that such extensions would be in the best interest of the Partnership. 2. Significant Accounting Policies Valuation of Investments - Short-term investments are carried at amortized cost which approximates market. Portfolio investments are carried at fair value as determined quarterly by the Managing General Partner under the supervision of the Individual General Partners. The fair value of publicly-held portfolio securities is adjusted to the average closing public market price for the last five trading days of each quarter discounted by a factor of 0% to 50% for sales restrictions. Factors considered in the determination of an appropriate discount include, underwriter lock-up or Rule 144 trading restrictions, insider status where the Partnership either has a representative serving on the company's Board of Directors or is greater than a 10% shareholder, and other liquidity factors such as the size of the Partnership's position in a given company compared to the trading history of the public security. Privately-held portfolio securities are carried at cost until significant developments affecting the portfolio company provide a basis for change in valuation. The fair value of private securities is adjusted 1) to reflect meaningful third-party transactions in the private market or 2) to reflect significant progress or slippage in the development of the company's business such that cost is no longer reflective of fair value. As a venture capital investment fund, the Partnership's portfolio investments involve a high degree of business and financial risk that can result in substantial losses. The Managing General Partner considers such risks in determining the fair value of the Partnership's portfolio investments. Investment Transactions - Investment transactions are recorded on the accrual method. Portfolio investments are recorded on the trade date, the date the Partnership obtains an enforceable right to demand the securities or payment therefor. Realized gains and losses on investments sold are computed on a specific identification basis. ML VENTURE PARTNERS II, L.P. NOTES TO FINANCIAL STATEMENTS Income Taxes - No provision for income taxes has been made since all income and losses are allocable to the Partners for inclusion in their respective tax returns. The Partnership's net assets for financial reporting purposes differ from its net assets for tax purposes. Net unrealized appreciation of investments of $22.5 million at December 31, 1994, which was recorded for financial statement purposes, was not recognized for tax purposes. Additionally, from inception to December 31, 1994, timing differences relating to realized losses totaling $1.6 million have been deducted on the Partnership's financial statements and syndication costs relating to the selling of Units totaling $11.3 million were charged to partners' capital on the financial statements. These amounts have not been deducted or charged against partners' capital for tax purposes. Statements of Cash Flows - The Partnership considers its interest-bearing cash account to be cash equivalents. 3. Allocation of Partnership Profits and Losses The Partnership Agreement provides that the Managing General Partner will be allocated, on a cumulative basis over the life of the Partnership, 20% of the Partnership's aggregate investment income and net realized gains and losses from venture capital investments, provided that such amount is positive. All other gains and losses of the Partnership are allocated among all the Partners (including the Managing General Partner) in proportion to their respective capital contributions to the Partnership. From its inception to December 31, 1994, the Partnership had a $12.0 million net gain from its venture capital investments, which includes interest and other income from portfolio investments totaling $2.4 million. 4. Related Party Transactions The Management Company performs, or arranges for others to perform, the management and administrative services necessary for the operation of the Partnership and receives a management fee at the annual rate of 2.5% of the gross capital contributions to the Partnership, reduced by selling commissions, organizational and offering expenses paid by the Partnership, capital distributed and realized capital losses with a minimum annual fee of $200,000. Such fee is determined and payable quarterly. On November 9, 1994, the Securities and Exchange Commission (the "SEC") issued an exemptive order permitting the Partnership to acquire 97,273 shares of Corporate Express, Inc. common stock from the Management Company subject to certain conditions, including review and approval by the Independent General Partners. On December 13, 1994, the Partnership purchased such shares for $1,111,685, representing original cost of $1,069,998 plus interest expense of $41,687. ML VENTURE PARTNERS II, L.P. NOTES TO FINANCIAL STATEMENTS During 1992, the Partnership purchased five portfolio investments from the Management Company after the receipt of the appropriate SEC exemptive orders and subsequent review and approval by the Independent General Partners. The Partnership purchased such investments from the Management Company for $3,404,586 representing reimbursement of the original cost of such investments totaling $3,224,065 plus $180,521 of interest expense. 5. Independent General Partners' Fees As compensation for services rendered to the Partnership, each of the three Independent General Partners receives $19,000 annually in quarterly installments, $1,200 for each meeting of the General Partners attended or for each other meeting, conference or engagement in connection with Partnership activities at which attendance by an Independent General Partner is required and $1,200 for each committee meeting attended ($500 if a committee meeting is held on the same day as a meeting of the General Partners). 6. Commitments The Partnership has a $393,043 non-interest bearing obligation payable on demand to MLMS Cancer Research, Inc. 7. Cash Distributions Cash distributions paid to Partners during 1994, 1993 and 1992 and cumulative cash distributions paid from inception of the Partnership through December 31, 1994 are listed below: Managing Distribution General Limited Per $1,000 Date Partner Partners Unit ---- ------- -------- ---- April 30, 1992 $ 9,000,000 $ 75 May 26, 1993 $ 15,600,000 $ 130 May 26, 1994 $ 16,200,000 $ 135 September 1, 1994 $ 1,400,000 Cumulative totals $ 1,400,000 $ 58,800,000 $ 490
Additionally, on March 1, 1995, the General Partners approved a cash distribution to Partners totaling $11.2 million; $9 million, or $75 per unit, to the Limited Partners and $2.2 million to the Managing General Partner. The distribution will be paid in April 1995 to Limited Partners of record on March 31, 1995 and will bring cumulative cash distributions paid to Limited Partners to $67.8 million, or $565 per $1,000 Unit. Cumulative cash distributions paid to the Managing General Partner will total $3.6 million. ML VENTURE PARTNERS II, L.P. NOTES TO FINANCIAL STATEMENTS 8. Pending Litigation The Partnership has been named as a defendant, along with other entities and individuals, in an action involving In-Store Advertising, Inc. ("ISA"). The action is a purported class action suit wherein the plaintiffs, who purchased shares of ISA in its July 19, 1990 initial public offering through November 8, 1990, allege violations under certain sections of the Securities Act of 1933, the Securities Exchange Act of 1934 and common law. The plaintiffs seek rescission of their purchases of ISA common stock together with damages and certain costs and expenses. The Partnership believes it has meritorious defenses to the allegations and that the cost of resolution of the litigation will not have a material impact on the financial condition and results of operations of the Partnership. During 1994, the Partnership incurred legal expenses totaling $148,000 related to the litigation. No additional expenses relating to the litigation were incurred in prior periods. 9. Short-Term Investments At December 31, 1994 and 1993, the Partnership had investments in short-term securities as detailed below. Maturity Purchase Amortized Issuer Yield Date Price Cost Face Value Investments in Commercial Paper at December 31, 1994: Cooperative Association of Tractor Dealers 5.50% 1/13/95 $ 1,975,556 $ 1,996,028 $ 2,000,000 Cooperative Association of Tractor Dealers 6.12% 3/10/95 2,466,850 2,470,675 2,500,000 MultiBanco Comermex, S.A. 6.15% 3/15/95 2,467,115 2,468,396 2,500,000 --------- --------- --------- Total $ 6,909,521 $ 6,935,099 $ 7,000,000 = ========= = ========= = ========= Investments in Commercial Paper at December 31, 1993: Golden Managers Acceptance Corporation 3.35% 1/19/94 $ 1,988,275 $ 1,996,464 $ 2,000,000 Golden Managers Acceptance Corporation 3.30% 1/26/94 1,991,933 1,995,233 2,000,000 --------- --------- --------- Total $ 3,980,208 $ 3,991,697 $ 4,000,000 = ========= = ========= = =========
ML VENTURE PARTNERS II, L.P. NOTES TO FINANCIAL STATEMENTS 10. Subsequent events Subsequent to the end of 1994, the Partnership sold 104,486 shares of Komag Incorporated common stock for $3 million and 510,000 shares of Regeneron Pharmaceuticals, Inc. for $3.3 million. These shares were valued at $4.3 million at December 31, 1994 reflecting the Partnership's standard valuation policy for publicly traded securities. Proceeds received in 1995 from the sale of these securities totaled $6.4 million. Had these securities been valued at their final liquidation values, the Partnership's net assets would have increased $2 million, or $13 per $1,000 unit, at December 31, 1994. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures. None PART III Item 10. Directors and Executive Officers of the Registrant. The Partnership The information set forth under the caption "Election of General Partners" in the Partnership's proxy statement in connection with the 1995 Annual Meeting of Limited Partners to be filed with the Securities and Exchange Commission pursuant to Regulation 14A under the Securities Exchange Act of 1934 (the "Proxy Statement") is incorporated herein by reference. The Management Company The Management Company performs, or arranges for others to perform, the management and administrative services necessary for the operation of the Partnership pursuant to a Management Agreement, dated as of May 23, 1991, between the Partnership and the Management Company. At March 15, 1995, the directors of the Management Company and the officers of the Management Company involved in the administrative support of the Partnership are: Served in Present Name and Age Position Held Capacity Since Kevin K. Albert (42) Director April 2, 1990 President July 5, 1991 Robert F. Aufenanger (41) Director April 2, 1990 Executive Vice President February 2, 1993 Robert W. Seitz (48) Director February 1, 1993 Vice President February 2, 1993 Joseph W. Sullivan (37) Treasurer February 2, 1993
The directors of the Management Company will serve as directors until the next annual meeting of stockholders and until their successors are elected and qualify. The officers of the Management Company will hold office until the next annual meeting of the Board of Directors of the Management Company and until their successors are elected and qualify. Information with respect to Messrs. Aufenanger, Seitz and Sullivan is set forth under Item 13 "Certain Relationships and Related Transactions". The information with respect to Mr. Albert set forth under the subcaption "Individual General Partners" in the Proxy Statement is incorporated herein by reference. There are no family relationships among any of the Individual General Partners of the Partnership and the officers and directors of the Management Company. Item 11. Executive Compensation. The information with respect to the compensation of the Individual General Partners set forth under the subcaption "Individual General Partners - Compensation" in the Proxy Statement is incorporated herein by reference. The information with respect to the allocation and distribution of the Partnership's profits and losses to the Managing General Partner set forth under the subcaption "Managing General Partner - Allocations and Distributions" in the Proxy Statement is incorporated herein by reference. The information with respect to the management fee payable to the Management Company set forth under the subcaption "Terms of Contracts - Management Fee" in the Proxy Statement is incorporated herein by reference. The information with respect to the sub-management fee payable to the Sub-Manager set forth under the subcaption "Terms of Contracts - Sub-Management Agreement" in the Proxy Statement is incorporated herein by reference. The Management Company has arranged for Palmeri Fund Administrators, Inc., an independent administrative services company, to provide administrative services to the Partnership. Fees for such services are paid directly by the Management Company. Item 12. Security Ownership of Certain Beneficial Owners and Management. The information concerning the security ownership of the Individual General Partners set forth under the subcaption "Individual General Partners" in the Partnership's Proxy Statement is incorporated herein by reference. As of March 15, 1995, no person or group is known by the Partnership to be the beneficial owner of more than 5 percent of the Units. Mark Clein and Stephen Warner, limited partners of the Managing General Partner, own 134 Units of the Partnership. The Individual General Partners and the directors and officers of the Management Company do not own any Units. The Partnership is not aware of any arrangement which may, at a subsequent date, result in a change of control of the Partnership. Item 13. Certain Relationships and Related Transactions. Kevin K. Albert, a Director and President of the Management Company and a Managing Director of Merrill Lynch Investment Banking Group ("ML Investment Banking"), joined Merrill Lynch in 1981. Robert F. Aufenanger, a Director and Executive Vice President of the Management Company, a Vice President of Merrill Lynch & Co. Corporate Strategy, Credit and Research and a Director of the Partnership Management Department, joined Merrill Lynch in 1980. Messrs. Albert and Aufenanger are involved with certain other entities affiliated with Merrill Lynch or its affiliates. Robert W. Seitz, a Director and Vice President of the Management Company, a First Vice President of Merrill Lynch & Co. Corporate Strategy, Credit and Research and a Managing Director within the Corporate Credit Division of Merrill Lynch, joined Merrill Lynch in 1981. Joseph W. Sullivan, a Treasurer of the Management Company and a Vice President of ML Investment Banking, joined Merrill Lynch in 1990. From 1988 to 1990, Mr. Sullivan was an Assistant Vice President with Standard & Poor's Debt Rating Group. PART IV Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K. (a) 1. Financial Statements Balance Sheets as of December 31, 1994 and 1993 Schedule of Portfolio Investments as of December 31, 1994 Schedule of Portfolio Investments as of December 31, 1993 Statements of Operations for the years ended December 31, 1994, 1993 and 1992 Statements of Cash Flows for the years ended December 31, 1994, 1993 and 1992 Statements of Changes in Partners' Capital for the years ended December 31, 1992, 1993 and 1994 Notes to Financial Statements 2. Exhibits (3) (a) Amended and Restated Certificate of Limited Partnership of the Partnership, dated as of January 12, 1987. (1) (3) (b) Amended and Restated Certificate of Limited Partnership of the Partnership, dated July 27, 1990.(2) (3) (c) Amended and Restated Certificate of Limited Partnership of the Partnership, dated March 25, 1991. (3) (3) (d) Amended and Restated Agreement of Limited Partnership of the Partnership, dated as of May 4, 1987. (4) (3) (e) Amendment No. 1 dated February 14, 1989 to Amended and Restated Agreement of Limited Partnership of the Partnership. (5) (3) (f) Amendment No. 2 dated July 27, 1990 to Amended and Restated Agreement of Limited Partnership of the Partnership. (2) (3) (g) Amendment No. 3 dated March 25, 1991 to Amended and Restated Agreement of Limited Partnership of the Partnership. (3) (3) (h) Amendment No. 4 dated May 23, 1991 to Amended and Restated Agreement of Limited Partnership of the Partnership. (6) (10) (a) Management Agreement dated as of May 23, 1991 among the Partnership, Management Company and the Managing General Partner. (6) (10) (b) Form of Sub-Management Agreement among the Partnership, Management Company, the Managing General Partner and the Sub-Manager. (8) (13) (a) Page 15 of the Quarterly Report on Form 10-Q for the quarter ended March 31, 1994. (13) (b) Page 15 of the Quarterly Report on Form 10-Q for the quarter ended June 30, 1994. (13) (c) Page 18 of the Quarterly Report on Form 10-Q for the quarter ended September 30, 1994. (27) Financial Data Schedule. (28) Prospectus of the Partnership dated February 10, 1987 filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as supplemented by a supplement thereto dated April 21, 1987 filed pursuant to Rule 424(c) under the Securities Act of 1933. (7) (b) No reports on Form 8-K have been filed since the beginning of the last quarter of the period for which this report is filed. (1) Incorporated by reference to the Partnership's Annual Report on Form 10-K for the year ended December 31, 1988 filed with the Securities and Exchange Commission on March 27, 1989. (2) Incorporated by reference to the Partnership's Quarterly Report on Form 10-Q for the quarter ended December 31, 1990 filed with the Securities and Exchange Commission on November 14, 1990. (3) Incorporated by reference to the Partnership's Annual Report on Form 10-K for the year ended December 31, 1990 filed with the Securities and Exchange Commission on March 28, 1991. (4) Incorporated by reference to the Partnership's Quarterly Report on Form 10-Q for the quarter ended June 30, 1987 filed with the Securities and Exchange Commission on August 14, 1987. (5) Incorporated by reference to the Partnership's Quarterly Report on Form 10-Q for the quarter ended March 31, 1989 filed with the Securities and Exchange Commission on May 15, 1989. (6) Incorporated by reference to the Partnership's Quarterly Report on Form 10-Q for the quarter ended June 30, 1991 filed with the Securities and Exchange Commission on August 14, 1991. (7) Incorporated by reference to the Partnership's Quarterly Report on Form 10-Q for the quarter ended March 31, 1987 filed with the Securities and Exchange Commission on May 15, 1987. (8) Incorporated by reference to the Partnership's Annual Report on Form 10-K for the year ended December 31, 1992 filed with the Securities and Exchange Commission on March 26, 1993.
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 27th day of March 1995. ML VENTURE PARTNERS II, L.P. /s/ Kevin K. Albert By: Kevin K. Albert General Partner Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on the 27th day of March 1995. By: MLVPII Co., L.P. By: /s/ Steward S. Flaschen its Managing General Partner Steward S. Flaschen Individual General Partner By: Merrill Lynch Venture Capital Inc. ML Venture Partners II, L.P. its General Partner By: /s/ Kevin K. Albert By: /s/ Jerome Jacobson ----------------------- ----------------------- Kevin K. Albert Jerome Jacobson President Individual General Partner (Principal Executive Officer) ML Venture Partners II, L.P. By: /s/ Joseph W. Sullivan By: /s/ William M. Kelly Joseph W. Sullivan William M. Kelly Treasurer Individual General Partner (Principal Financial and Accounting Officer) ML Venture Partners II, L.P.
EX-13.(A) 2 EXHIBIT 13.(A) Exhibit 13(a) On February 1, 1994, the Partnership purchased 55,238 shares of preferred stock of Viasoft, Inc. for $69,048. This investment is in addition to the 806,647 shares of preferred stock previously owned by the Partnership. EX-13.(B) 3 EXHIBIT 13.(B) Exhibit 13(b) On May 23, 1994, the Partnership purchased 232,298 shares of preferred stock of Photon Dynamics, Inc. for $418,136. This investment is in addition to the 990,530 shares of preferred stock previously owned by the Partnership. On June 21, 1994, the Partnership purchased a 9.25% convertible note of Neocrin Corporation for $317,592. This investment is in addition to the 1,586,831 shares of preferred stock previously owned by the Partnership. EX-13.(C) 4 EXHIBIT 13.(C) Exhibit 13(c) During the quarter, the Partnership purchased 10,000 shares of CellPro, Incorporated for $105,000. This investment is in addition to the 413,333 shares of common stock previously owned by the Partnership. EX-27 5 EXHIBIT 27
6 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ML VENTURE PARTNERS II, L.P.'S ANNUAL REPORT ON FORM 10-K FOR THE PERIOD ENDED DECEMBER 31, 1994 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. YEAR DEC-31-1994 JAN-1-1994 DEC-31-1994 52,936,366 75,400,208 822,126 0 7,573,967 83,796,301 0 0 393,822 393,822 0 0 0 0 0 0 0 0 22,463,842 83,402,479 279,298 910,520 0 2,006,744 (816,926) 18,592,821 (29,444,350) (11,668,455) 0 0 0 17,600,000 0 0 0 (29,290,860) 0 0 0 0 0 41,687 0 0 852 0 0 0 135 0 638 0 0 0
-----END PRIVACY-ENHANCED MESSAGE-----